| Abstract: | On the basis of specific criteria, serotonin (5-HT) receptors are categorised into seven major families (5-HT1 – 5-HT7), of which 5-HT7 receptors represent one of the newest populations. Although evidence suggests that 5-HT7 receptors, which are found both centrally and peripherally, might be involved in various central disorders, such as depression, psychosis and cognitive impairment, as well as in circadian rhythm, sleep physiology and cardiovascular function, only recently have selective agents been identified to better assess their role. 5-HT7 receptors are certainly viable targets for drug development. Egis Pharmaceuticals identified a series of oxindole analogues that bind at 5-HT7 receptors and are claimed to be of possible benefit in the treatment of central disorders. |
